Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alaunos Therapeutics
Company Location: BOSTON MA 02129
Company CEO: Kevin S. Boyle
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Lung Cancer|Sarcoma
Phase 2: Sarcoma|Breast Cancer|Germinoma|Teratoma|Seminoma|Testicular Cancer
Phase 1: Thymoma|Ovarian Cancer|Oncology Unspecified|Osteosarcoma|Non-Small-Cell Lung Cancer|Testicular Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
The MATISSE Study | P3 |
Unknown status |
Small Cell Lung Cancer |
2015-06-01 |
|
2011-006134-17 | P3 |
Completed |
Small Cell Lung Cancer |
2014-12-03 |
|
ATI001-201 | P2 |
Completed |
Breast Cancer |
2014-12-01 |
|
IUCRO-0403 | P2 |
Terminated |
Seminoma|Testicular Cancer|Germinoma|Teratoma |
2014-11-01 |